PHASE-II TRIAL OF CARBOPLATIN IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY GROUP
PHASE-II TRIAL OF CARBOPLATIN IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY GROUP
复制标题
DOI：
10.1097/00000421-199304000-00015
复制
发表时间：
1993-04-01
影响因子：
2.6
通讯作者：
SMITH, TJ
中科院分区：
文献类型：
--
作者：
CHANG, A;HUNT, M;SMITH, TJ
30例经病理证实的、可测量的转移性黑色素瘤患者，既往未接受过化疗，接受卡铂400 mg/m2静脉输注30分钟，每4周一次。27例患者可评价反应和毒性。记录了2例完全缓解和1例部分缓解（3/27 = 11%，90%置信区间：3-26%）。中位生存期为4.7个月。最常见的毒性反应是骨髓抑制。观察到1例药物相关性死亡是由于肾衰竭。在我们的研究中，既往放疗和肝转移是预后不良的指标。在我们的试验中报告的剂量和时间表中的卡铂在晚期恶性黑色素瘤患者中仅具有适度的抗肿瘤活性。
Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11%, 90% confidence intervals: 3-26%) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.